What are the opening hours?

Monday 9am - 5pm Tuesday 9am - 5pm Wednesday 9am - 5pm Thursday 9am - 5pm Friday 9am - 5pm

Daxor Corporation

Home
United States
Oak Ridge, TN
Daxor Corporation

Committed to advancing the field of healthcare by enabling optimal fluid management with blood volume analysis. (NYSE: $DXR)

02/20/2026

Why are "normal" lab results leaving Long COVID patients without answers? 🤔

A new case study reveals that standard hematocrit tests can mask serious underlying issues. While patient "Jenny" appeared healthy on paper, Blood Volume Analysis (BVA) unmasked a 18.2% total volume and 21.8% red cell deficit.

By moving from guesswork to precision, BVA identifies the objective volume phenotypes needed to provide targeted, effective treatment for dysautonomia and fatigue.

Read how BVA is uncovering some of the invisible drivers of Long COVID in this months : https://www.linkedin.com/posts/daxorcorporation_bvabrief-longcovid-dysautonomia-activity-7430685327515701248-iei6?utm_source=share&utm_medium=member_desktop&rcm=ACoAAAMGo4ABzJtW1kRfkqctXbzjRcnEurq3iSM

11/10/2025

📉Routine BVA before LVAD surgery cut 30-day readmissions from 28.6% to 16.3%. Post-op dialysis dropped from 34% to 10.6%.
🚨Better volume data upfront = better treatment decisions.
🔗Read more: https://linkedin.com/posts/daxorcorporation_bva-lvad-activity-7393721933735047168-P91Q?utm_source=share&utm_medium=member_desktop&rcm=ACoAAAMGo4ABzJtW1kRfkqctXbzjRcnEurq3iSM
Wellstar Health System

10/31/2025

LVAD Outcomes Just Got Better!

New data from Wellstar Health System presented at shows a perioperative strategy featuring significantly reduces complications and boosts survival for patients:

1-Year Survival: Increased from 79.6% to 87.8%
Kidney Injury (RRT): Dropped from 34.1% to 10.6%
Readmissions: Down from 28.6% to 16.3%
Post-Operative Length of Stay: Decreased by 1.5 days

BVA is helping clinicians optimize care and improve long-term results!

Learn more: https://www.linkedin.com/posts/daxorcorporation_hfsa-cardiology-lvadcare-activity-7390070113082695680-rVAJ?utm_source=share&utm_medium=member_desktop&rcm=ACoAAAMGo4ABzJtW1kRfkqctXbzjRcnEurq3iSM

10/28/2025

❓If 92% of your Cardiac Amyloidosis patients are volume overloaded, can you afford to rely on subjective tools that have already failed to see it?

🔗Read more: https://linkedin.com/posts/daxorcorporation_cardiacamyloidosis-bva-activity-7389039681407184897-Pjv5?utm_source=share&utm_medium=member_desktop&rcm=ACoAAAMGo4ABzJtW1kRfkqctXbzjRcnEurq3iSM

10/21/2025

🚨CEO Michael Feldschuh is engaging institutional investors at the invitation only Maxim Growth Summit in NYC (Oct 22–23).

🔗https://daxor.com/daxor-ceo-michael-feldschuh-to-engage-investors-at-exclusive-maxim-growth-summit/

Nasdaq
Maxim

10/15/2025

🚀 Daxor is proud to debut our awaited new BVA diagnostic system at the MedAxiom - An ACC Company CV Transforum Fall '25 in Austin (Oct. 16-18).

🤝 We are excited to be connecting with leaders in cardiovascular care to showcase how our new diagnostic is the catalyst to tackle key challenges like hospital readmissions and resource optimization.

🔗Read more: https://daxor.com/daxors-new-bva-technology-to-be-showcased-at-medaxiom-cv-transforum-fall-25/

Nasdaq

09/30/2025

🏆 The Standard of Care Just Changed: Data from HFSA Validates BVA as Essential Diagnostic.

"Clinical findings provide undeniable evidence that BVA is an essential diagnostic for improving care and reducing costs,” – John L. Jefferies, MD, MPH, MBA, CMO.

This definitive statement follows the debut of our FDA-cleared, next-generation BVA analyzer and the presentation of pivotal data:

✅ Banner UMC: Showed ZERO unplanned readmissions for patients guided by BVA.

✅ Wellstar Health: Demonstrated substantial cuts in AKI/RRT, readmissions, and length of stay for LVAD patients.

✅ Geisinger Medical Center: Showed BVA identifies a unique phenotype in cardiac amyloidosis, assisting clinicians with accurate diuretic dosing.

This substantial clinical validation positions Daxor to ensure BVA technology becomes widely accessible, making its benefits available to all patients.

Read more: https://daxor.com/daxor-unveils-new-fda-cleared-bva-analyzer-amid-strong-market-demand-and-pivotal-clinical-data-at-hfsa/

Nasdaq
Banner Health
Geisinger
Wellstar Health System

09/25/2025

The problem of imprecise fluid management is the inability to precisely measure blood volume. Our new BVA system solves this with over 95% accuracy in a rapid, lightweight, battery-operated device. See it at Device Day & Booth #1007 at .

09/23/2025

🎉We're headed to for the official debut of our new, FDA-cleared BVA analyzer. This next-gen device is a game-changer for data-driven fluid management. Read more: https://daxor.com/daxor-corporation-unveils-breakthrough-next-gen-bva-analyzer-at-hfsa-annual-scientific-meeting/
Nasdaq

09/22/2025

"Blood Volume Analysis is like an EKG for volume" - my colleague's insight perfectly captures where precision medicine is heading. Read more: https://www.linkedin.com/posts/daxorcorporation_bva-heartfailure-activity-7375876541596979200-vuVi?utm_source=share&utm_medium=member_desktop&rcm=ACoAAAMGo4ABzJtW1kRfkqctXbzjRcnEurq3iSM

09/19/2025

Attending HFSA 2025? So are we! Stop by Device Day or find us at booth 1007 for a live demonstration of our new BVA analyzer. We're looking forward to connecting with you and sharing this exciting advancement.

09/04/2025

Learn how our technology is changing . A new pilot study published in the Journal of Critical Care reveals frequent inaccuracies in traditional fluid assessments, reinforcing the need for our solution.
Read more: https://daxor.com/5716-2/?utm_source=mailpoet&utm_medium=email&utm_source_platform=mailpoet

Nasdaq

Address

107 Meco Lane
Oak Ridge, TN
37830

Opening Hours

Monday	9am - 5pm
Tuesday	9am - 5pm
Wednesday	9am - 5pm
Thursday	9am - 5pm
Friday	9am - 5pm

Website

https://www.daxor.com/

Alerts

Be the first to know and let us send you an email when Daxor Corporation posts news and promotions. Your email address will not be used for any other purpose, and you can unsubscribe at any time.

Contact The Practice

Send a message to Daxor Corporation:

Shortcuts

Want your practice to be the top-listed Clinic in Oak Ridge?

Our Story

Our Mission It is our goal to partner with hospitals and physicians to integrate direct blood volume measurement into standard clinical practice.

https://youtu.be/4a1dXHRfY6o

About Us Daxor Corporation is an innovative medical instrumentation and biotechnology company focused on blood volume analysis. We manufacture the BVA-100 Blood Volume Analyzer; the only rapid, clinically-available, FDA-cleared diagnostic to provide direct measurement of a patient’s blood volume in a broad range of medical conditions.

Transforming Healthcare Dozens of peer-reviewed studies have established the value of Daxor’s diagnostic, confirming that accurate blood volume analysis leads to better informed physicians, better treatment strategies, and improves patient outcomes and resource utilization.